Kyverna Therapeutics (NASDAQ:KYTX) Price Target Lowered to $4.00 at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX) had its price objective lowered by research analysts at HC Wainwright from $6.00 to $4.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 86.05% from the company’s current price.

Separately, Morgan Stanley lowered their price target on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $18.33.

Kyverna Therapeutics Trading Up 8.6 %

NASDAQ:KYTX opened at $2.15 on Thursday. Kyverna Therapeutics has a 12-month low of $1.88 and a 12-month high of $24.91. The firm has a market cap of $92.82 million and a PE ratio of -0.62. The stock has a fifty day moving average price of $2.76 and a 200 day moving average price of $4.03.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.01). Equities analysts forecast that Kyverna Therapeutics will post -3.29 EPS for the current year.

Hedge Funds Weigh In On Kyverna Therapeutics

Several hedge funds have recently added to or reduced their stakes in KYTX. Charles Schwab Investment Management Inc. lifted its position in shares of Kyverna Therapeutics by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,780 shares of the company’s stock worth $635,000 after buying an additional 3,145 shares during the last quarter. Corebridge Financial Inc. boosted its stake in Kyverna Therapeutics by 42.3% in the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock valued at $48,000 after acquiring an additional 3,810 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kyverna Therapeutics by 53.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company’s stock worth $53,000 after purchasing an additional 4,990 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock valued at $97,000 after purchasing an additional 6,153 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after purchasing an additional 6,400 shares during the last quarter. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.